Pediatric Gliomas: Molecular Landscape and Emerging Targets

Sophie M. Peeters, Yagmur Muftuoglu, Brian Na, David J. Daniels, Anthony C. Wang

Research output: Contribution to journalReview articlepeer-review


Next-generation sequencing of pediatric gliomas has revealed the importance of molecular genetic characterization in understanding the biology underlying these tumors and a breadth of potential therapeutic targets. Promising targeted therapies include mTOR inhibitors for subependymal giant cell astrocytomas in tuberous sclerosis, BRAF and MEK inhibitors mainly for low-grade gliomas, and MEK inhibitors for NF1-deficient BRAF:KIAA fusion tumors. Challenges in developing targeted molecular therapies include significant intratumoral and intertumoral heterogeneity, highly varied mechanisms of treatment resistance and immune escape, adequacy of tumor penetrance, and sensitivity of brain to treatment-related toxicities.

Original languageEnglish (US)
Pages (from-to)181-190
Number of pages10
JournalNeurosurgery clinics of North America
Issue number2
StatePublished - Apr 2021


  • Diffuse midline glioma
  • Histone mutation
  • Molecular genetics
  • Next-generation sequencing
  • Pediatric glioma
  • Targeted therapy

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology


Dive into the research topics of 'Pediatric Gliomas: Molecular Landscape and Emerging Targets'. Together they form a unique fingerprint.

Cite this